These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 17538553

  • 1. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR, Gobburu JV.
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC, Cross JT.
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract] [Full Text] [Related]

  • 4. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ, Lalonde RL.
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J.
    New Yorker; 2006 Dec 18; ():40-7. PubMed ID: 17176539
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Food and Drug Administration: 100 years of protection.
    Mosocco DJ.
    Home Healthc Nurse; 2007 Mar 18; 25(3):148-50. PubMed ID: 17353704
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y, Bhattaram AV, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, Qiu W, Sun H, Yim DS, Zheng JJ, Gobburu JV.
    J Clin Pharmacol; 2008 Feb 18; 48(2):146-56. PubMed ID: 18199891
    [Abstract] [Full Text] [Related]

  • 13. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q, Chi GY.
    J Biopharm Stat; 2010 Nov 18; 20(6):1178-219. PubMed ID: 21058114
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT, Barash PG.
    Anesth Analg; 2009 Jan 18; 108(1):211-8. PubMed ID: 19095852
    [Abstract] [Full Text] [Related]

  • 17. ASCPT Task Force for advancing pharmacometrics and integration into drug development.
    Goldberger MJ, Singh N, Allerheiligen S, Gobburu JV, Lalonde R, Smith B, Ryder S, Yozviak A.
    Clin Pharmacol Ther; 2010 Aug 18; 88(2):158-61. PubMed ID: 20648032
    [Abstract] [Full Text] [Related]

  • 18. Drug development history, "overview," and what are GCPs?
    Heilman RD.
    Qual Assur; 1995 Mar 18; 4(1):75-9. PubMed ID: 8520867
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
    Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang Y, Tandon V, Duan JZ, Baweja RK, Marroum PJ, Uppoor RS, Rahman NA, Sahajwalla CG, Powell JR, Mehta MU, Gobburu JV.
    AAPS J; 2005 Oct 07; 7(3):E503-12. PubMed ID: 16353928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.